EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The contribution of the sphingosine 1-phosphate signaling pathway to chronic kidney diseases: recent findings and new perspectives

Stephanie Schwalm, Roxana Manaila, Anke Oftring, Liliana Schaefer, Stephan von Gunten, Josef Pfeilschifter

Pflügers Archiv - European Journal of Physiology · 2024

DOI: 10.1007/s00424-024-03029-5 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pflügers Archiv - European Journal of Physiology, 2024. Verfasst von Stephanie Schwalm und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institut für Allgemeine Pharmakologie und Toxikologie, Goethe-Universität Frankfurt Am Main, Theodor-Stern-Kai 7, 60590, Frankfurt Am Main, Germany. …. Hauptthemen laut MEDLINE: Lysophospholipids, Sphingosine, Signal Transduction, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 130 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: LOEWE Initiative, Deutsche Forschungsgemeinschaft, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic kidney disease (CKD) is a multifactorial condition with diverse etiologies, such as diabetes mellitus, hypertension, and genetic disorders, often culminating in end-stage renal disease (ESRD). A hallmark of CKD progression is kidney fibrosis, characterized by the excessive accumulation of extracellular matrix components, for which there is currently no effective anti-fibrotic therapy. Recent literature highlights the critical role of sphingosine 1-phosphate (S1P) signaling in CKD pathogenesis and renal fibrosis. This review provides an in-depth analysis of the latest findings on S1P metabolism and signaling in renal fibrosis and in specific CKDs, including diabetic nephropathy (DN), lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS), Fabry disease (FD), and IgA nephropathy (IgAN). Emerging studies underscore the therapeutic potential of modulating S1P signaling with receptor modulators and inhibitors, such as fingolimod (FTY720) and more selective agents like ozanimod and cenerimod. Additionally, the current knowledge about the effects of established kidney protective therapies such as glucocorticoids and SGLT2 and ACE inhibitors on S1P signaling will be summarized. Furthermore, the review highlights the potential role of S1P as a biomarker for disease progression in CKD models, particularly in Fabry disease and diabetic nephropathy. Advanced technologies, including spatial transcriptomics, are further refining our understanding of S1P’s role within specific kidney compartments. Collectively, these insights emphasize the need for continued research into S1P signaling pathways as promising targets for CKD treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LysophospholipidsSphingosineSignal TransductionRenal Insufficiency, ChronicHumansAnimalsFibrosis

Stichwörter der Autor:innen

Diabetes mellitusFibrosisGlomerulosclerosisInflammationSphingosine kinaseTGF-β

Substanzen

Lysophospholipidssphingosine 1-phosphateSphingosine

Autor:innen und Institutionen

  • Institut für Allgemeine Pharmakologie und Toxikologie, Goethe-Universität Frankfurt Am Main, Theodor-Stern-Kai 7, 60590, Frankfurt Am Main, Germany. S.Schwalm@med.uni-frankfurt.de.
  • Institut für Pharmakologie, Universität Bern, Inselspital, INO-F, CH-3011, Bern, Switzerland.
  • Institut für Allgemeine Pharmakologie und Toxikologie, Goethe-Universität Frankfurt Am Main, Theodor-Stern-Kai 7, 60590, Frankfurt Am Main, Germany.

Förderung

  • LOEWE Initiative
  • Deutsche Forschungsgemeinschaft
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
  • Fondation Leducq
  • Johann Wolfgang Goethe-Universität, Frankfurt am Main

Zitieren

APA

Schwalm, S., Manaila, R., Oftring, A., Schaefer, L., von Gunten, S., & Pfeilschifter, J. (2024). The contribution of the sphingosine 1-phosphate signaling pathway to chronic kidney diseases: recent findings and new perspectives. Pflügers Archiv - European Journal of Physiology. https://doi.org/10.1007/s00424-024-03029-5

Vancouver

Schwalm S, Manaila R, Oftring A, Schaefer L, von Gunten S, Pfeilschifter J. The contribution of the sphingosine 1-phosphate signaling pathway to chronic kidney diseases: recent findings and new perspectives. Pflügers Archiv - European Journal of Physiology. 2024. doi:10.1007/s00424-024-03029-5

BibTeX
@article{Schwalm2024,
  author = {Schwalm, Stephanie and Manaila, Roxana and Oftring, Anke and Schaefer, Liliana and von Gunten, Stephan and Pfeilschifter, Josef},
  title = {The contribution of the sphingosine 1-phosphate signaling pathway to chronic kidney diseases: recent findings and new perspectives},
  journal = {Pflügers Archiv - European Journal of Physiology},
  year = {2024},
  doi = {10.1007/s00424-024-03029-5}
}
Kostenlos starten →